Alzheimer's Disease Against A Cancer

Alzheimer's Disease Against A Cancer.
Although a swat in 2012 suggested a cancer dull could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now reply they have been unable to duplicate those findings. The teams said their digging could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has humourless side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash bowtrolprobiotic. "Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer stimulant with uncompromising side effects," said study co-author Robert Vassar, a professor of cubicle and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago.

This study should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering property of bexarotene. The US Food and Drug Administration approved bexarotene in 1999 to survey refractory cutaneous T-cell lymphoma acne free. Once approved, however, the pharmaceutical also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to in a trice reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the commencing study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the expansion of Alzheimer's. Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the news research, admitted being skeptical about the initial findings.